Market Research Report

Adalimumab Monoclonal Antibody Biosimilar Market, Global Outlook and Forecast 2023-2029

  • AMR ID : 7-3277
  • CAT ID : 7
  • Pages : 116
  • Date : Jun 2023
 

The global Adalimumab Monoclonal Antibody Biosimilar market was valued at US$ 433.2 million in 2022 and is projected to reach US$ 955.4 million by 2029, at a CAGR of 12.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report aims to provide a comprehensive presentation of the global market for Adalimumab Monoclonal Antibody Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Monoclonal Antibody Biosimilar. This report contains market size and forecasts of Adalimumab Monoclonal Antibody Biosimilar in global, including the following market information:
Global Adalimumab Monoclonal Antibody Biosimilar Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Adalimumab Monoclonal Antibody Biosimilar Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Adalimumab Monoclonal Antibody Biosimilar companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab Monoclonal Antibody Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab Monoclonal Antibody Biosimilar Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab Monoclonal Antibody Biosimilar Market Segment Percentages, by Type, 2022 (%)
Syringe
Pen
Global Adalimumab Monoclonal Antibody Biosimilar Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab Monoclonal Antibody Biosimilar Market Segment Percentages, by Application, 2022 (%)
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Global Adalimumab Monoclonal Antibody Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adalimumab Monoclonal Antibody Biosimilar Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adalimumab Monoclonal Antibody Biosimilar revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Adalimumab Monoclonal Antibody Biosimilar revenues share in global market, 2022 (%)
Key companies Adalimumab Monoclonal Antibody Biosimilar sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Adalimumab Monoclonal Antibody Biosimilar sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adalimumab Monoclonal Antibody Biosimilar, market overview.
Chapter 2: Global Adalimumab Monoclonal Antibody Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Adalimumab Monoclonal Antibody Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adalimumab Monoclonal Antibody Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adalimumab Monoclonal Antibody Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
1.1 Adalimumab Monoclonal Antibody Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adalimumab Monoclonal Antibody Biosimilar Overall Market Size
2.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size: 2022 VS 2029
2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Adalimumab Monoclonal Antibody Biosimilar Players in Global Market
3.2 Top Global Adalimumab Monoclonal Antibody Biosimilar Companies Ranked by Revenue
3.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Companies
3.4 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Companies
3.5 Global Adalimumab Monoclonal Antibody Biosimilar Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Adalimumab Monoclonal Antibody Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Adalimumab Monoclonal Antibody Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adalimumab Monoclonal Antibody Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Adalimumab Monoclonal Antibody Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Adalimumab Monoclonal Antibody Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Syringe
4.1.3 Pen
4.2 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Sales & Forecasts
4.3.1 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Adalimumab Monoclonal Antibody Biosimilar Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Market Size, 2022 & 2029
5.1.2 Ankylosing Spondylitis
5.1.3 Rheumatoid Arthritis
5.1.4 Crohn’s Disease
5.1.5 Other
5.2 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Sales & Forecasts
5.3.1 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Adalimumab Monoclonal Antibody Biosimilar Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Sales & Forecasts
6.3.1 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2029
6.4.3 US Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.4.4 Canada Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.4.5 Mexico Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2029
6.5.3 Germany Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.4 France Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.5 U.K. Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.6 Italy Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.7 Russia Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.5.9 Benelux Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2029
6.6.3 China Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.6.4 Japan Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.6.5 South Korea Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.6.7 India Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2029
6.7.3 Brazil Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.7.4 Argentina Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales, 2018-2029
6.8.3 Turkey Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.8.4 Israel Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
6.8.6 UAE Adalimumab Monoclonal Antibody Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Cadila Healthcare
7.1.1 Cadila Healthcare Company Summary
7.1.2 Cadila Healthcare Business Overview
7.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.1.5 Cadila Healthcare Key News & Latest Developments
7.2 Torrent Pharmaceuticals
7.2.1 Torrent Pharmaceuticals Company Summary
7.2.2 Torrent Pharmaceuticals Business Overview
7.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.2.5 Torrent Pharmaceuticals Key News & Latest Developments
7.3 Amgen
7.3.1 Amgen Company Summary
7.3.2 Amgen Business Overview
7.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.3.5 Amgen Key News & Latest Developments
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Company Summary
7.4.2 Boehringer Ingelheim Business Overview
7.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.4.5 Boehringer Ingelheim Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Samsung Bioepis
7.6.1 Samsung Bioepis Company Summary
7.6.2 Samsung Bioepis Business Overview
7.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.6.5 Samsung Bioepis Key News & Latest Developments
7.7 Viatris
7.7.1 Viatris Company Summary
7.7.2 Viatris Business Overview
7.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.7.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.7.5 Viatris Key News & Latest Developments
7.8 Pfizer
7.8.1 Pfizer Company Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Key News & Latest Developments
7.9 Fresenius Kabi
7.9.1 Fresenius Kabi Company Summary
7.9.2 Fresenius Kabi Business Overview
7.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.9.5 Fresenius Kabi Key News & Latest Developments
7.10 Coherus
7.10.1 Coherus Company Summary
7.10.2 Coherus Business Overview
7.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Major Product Offerings
7.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales and Revenue in Global (2018-2023)
7.10.5 Coherus Key News & Latest Developments
8 Global Adalimumab Monoclonal Antibody Biosimilar Production Capacity, Analysis
8.1 Global Adalimumab Monoclonal Antibody Biosimilar Production Capacity, 2018-2029
8.2 Adalimumab Monoclonal Antibody Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Adalimumab Monoclonal Antibody Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Adalimumab Monoclonal Antibody Biosimilar Supply Chain Analysis
10.1 Adalimumab Monoclonal Antibody Biosimilar Industry Value Chain
10.2 Adalimumab Monoclonal Antibody Biosimilar Upstream Market
10.3 Adalimumab Monoclonal Antibody Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Adalimumab Monoclonal Antibody Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

 
Choose License Type

Single User : $3250


Corporate User : $4225


Why Choose Us ?

24/7 Research support

Quality assurance

Information security

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Subscribe Newsletter

  Subscribe